Thermo Fisher opens new ultra-cold facility in Bleiswijk to expand clinical trial network
Thermo Fisher Scientific, a global leader in serving science, has unveiled its latest advancement in bioservices—a state-of-the-art ultra-cold facility located in Bleiswijk, Netherlands. This new facility is designed to bolster the clinical trial network within Europe and enhance the development of cutting-edge therapies.
At the forefront of its capabilities, the Bleiswijk facility specializes in the production and storage of high-value therapies, including cell and gene therapies, biologics, antibodies, and vaccines. Offering end-to-end support, it ensures pharma and biopharma customers can effectively manage their clinical supply chains, tailoring solutions to meet the specific demands of each stage of development.
Molly Flick, Vice President and General Manager, Bioservices & Specialty Logistics at Thermo Fisher Scientific, emphasized the significance of the new site, stating, “The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies.”
Strategically positioned just 30 minutes outside of Amsterdam, the facility extends over 5,000 square meters, offering a range of temperatures from ambient to cryogenic for optimal material storage. The site’s capabilities include clinical and commercial packaging, cold chain packaging, labeling, distribution, and clinical Qualified Person (QP) release services.
In alignment with Thermo Fisher’s commitment to environmental sustainability, the Bleiswijk facility operates with 15% solar power, is completely gas-free, and utilizes modern technologies such as eco-friendly electric heat pumps and heat recovery systems. This approach not only supports the company’s goal of achieving net-zero emissions by 2050 but also promotes sustainable practices within the industry.
The addition of the Bleiswijk facility to Thermo Fisher’s global network—which includes recent expansions in biologics manufacturing in St. Louis and a new cell therapy manufacturing site in San Francisco—further strengthens its capacity to support the burgeoning demand for cell and gene therapy clinical trials across Europe.
This expansion represents a significant stride in Thermo Fisher Scientific’s ongoing efforts to advance inclusive and impactful clinical research, ensuring that innovative therapies can be developed and delivered more efficiently and sustainably.